Usually Timolol maleate is well tolerated. Transient blurred vision (6.0%), lasting from 30 seconds to 5 minutes, following instillation was the most frequent drug-related complaint in clinical studies.
Other probable or possible drug related adverse reactions occurred with frequency of at least 1% in parallel active treatment controlled clinical trials include: Ocular: Burning and stinging, discharge, foreign body sensation, itching of the eye.
Other reported adverse reactions with ocular administration of this or other timolol maleate formulations, either in clinical trials or since the drug has been marketed include: Special Senses: Ocular irritation, including conjunctivitis, blepharitis, keratitis, decreased corneal sensitivity, and dry eyes. Visual disturbances, including refractive changes (due to withdrawal of miotic therapy in some cases), diplopia, ptosis, choroidal detachment following filtration surgery (see Warnings), tinnitus.
Cardiovascular: Bradycardia, arrhythmia, hypotension, syncope, heart block, cardiovascular accident, cerebral ischemia, congestive heart failure, palpitation, cardiac arrest, edema, claudication, Raynaud's phenomenon, cold hands and feet.
Respiratory: Bronchospasm (predominantly in patients with pre-existing bronchospastic disease), respiratory failure, dyspnea, cough.
Body as a Whole: Headache, asthenia, fatigue, chest pain.
Integumentary: Alopecia, psoriasiform rash or exacerbation of psoriasis.
Hypersensitivity: Signs and symptoms of allergic reactions including angioedema, urticaria, localized and generalized rash.
Nervous System/Psychiatric: Dizziness, depression, insomnia, nightmares, memory loss, paresthesia.
Neuromuscular: Increase in signs and symptoms of myasthenia gravis.
Digestive: Nausea, diarrhea, dyspepsia, dry mouth.
Urogenital: Decreased libido, Peyronie's disease.
Immunologic: Systemic lupus erythematosus.